Analytik Jena in the First Quarter with a Stable Business Development
(Thomson Reuters ONE) - Analytik Jena AG / Analytik Jena in the First Quarter with a Stable Business Development processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. - Sales increase is 25.7 % despite economic crisis- Operating result slightly down compared to previous year`s record numbers- Strong growth in Life ScienceJena/Germany, February 11, 2010 - With sales of EUR 21.6 m, Analytik Jena AG(Frankfurt DE0005213508, Prime Standard: AJA) has made a solid start to the newfinancial year, maintaining its position well despite an ongoing difficultmarket environment. This was the statement made by the Thuringia-based companytoday during the presentation of its three-months figures.Sales and EarningsIn the first quarter of the 2009/2010 financial year, Analytik Jena achievedconsolidated revenue of EUR 21.6 m and, including the acquired subsidiariesCybio and Biometra, accordingly recorded sales growth of 25.7 %. In operatingresults Analytik Jena recorded a slight fall. With an EBIT margin of 9.0 %,earnings before interest and taxes (EBIT) amounted to EUR 1.9 m, down 14.5 %year on year. Earnings per share were EUR 0.21."Altogether the Company recorded stable business development. In view of thefirst three months of the 2009/2010 financial year as expected Analytik Jenacould considerably grow in the business unit Life Science ",said Klaus Berka, CEO of Analytik Jena AG. "The operating results are below therecord quarter of the previous year, but considering the overall economicconditions and some special effects they are a good starting position tocontinue our growth in the current financial year ", Berka added.Alongside the positive influence of major projects in the previous year, thesignificantly weaker dollar together with a negative balance of financialexpenses to financial income, special amortization from the acquisitions and theunexpectedly large drop in Optics sales would also need to be taken into accountwhen comparing the quarters year on year.Above all in the important growth field of Life Science the Company madeimportant progress in setting the course in the first quarter. This is alsoreflected in the results of this segment. Altogether the Group achieved sales inthis segment of EUR 8.1 m, up by 488.9 % year on year. Both CyBio AG andBiometra GmbH contributed significantly to the sales of this business unit. Thebusiness unit also increased its sales organically by 30.8 %. For the first timeAnalytik Jena made a positive operating result in this business unit of EUR 0.5m EUR compared to EUR -0,2 m in the same period of the previous year.The business unit Analytical Instrumentation noted a slight sales decrease. Inview of the investment restraint due to the economic situation and the fact thatseveral major orders in the same period of the previous year had to becompensated, the sales fell slightly by 9.1 % and came to EUR 12.4 m. Theoperating results (EBIT) were accordingly down 33.4% from EUR 1.9 m to EUR 1.3m.The segment Optics achieved sales in the first three months of the financialyear of EUR 1.1 m and was therefore 50.6 % down on the previous year. Theincreasing competitive pressure in the consumer segment throughout the entiresector was felt most sharply in this business unit. The operating result was EUR0.2 m related to EUR 0.6 m in the same period of the previous year.Balance Sheet and Cash FlowThe Group's total assets remained virtually unchanged as of December 31, 2009,at EUR at EUR 75.2 m compared to EUR 75.5 m as of September 30, 2009. Equityincreased to EUR 39.7 m (September 30, 2009: EUR 38.4 m). This corresponds to anequity ratio of 52.9 %. The level of cash and cash equivalents rose to EUR 11.4m as at the end of the reporting period related to EUR 10.4 m as of September30, 2009.OutlookAs before, Analytik Jena expects to continue its positive development in thecurrent financial year. Stable incoming orders in the key business unitAnalytical Instrumentation, that are slightly above average of the previousfinancial year, make us confident to close the current sales gap in this segmentby the end of the financial year or even to exceed the revenue of the previousfinancial year. Especially the "analytica" in March 2010 in Munich is certain toact as a indicator for the further development in the second half of the year. Avariety of new products are supposed to further expand the business."For the current second quarter we expect a slight further sales growth in thebusiness unit Life Science and for the first time again in Optics as well. InAnalytical Instrumentation we will still be slightly down year on year. Thiswill also be reflected in the operating results with a comparatively moderateincrease. The revival of the US dollar over the past few weeks serves to supportour business model", Berka emphasizes.The 3-Month-Report can be downloaded athttp://berichte.analytik-jena.de/3-MonthReport_0910.pdfContact: Dana Schmidt, Media & Investor RelationsPhone: +49 36 41 77-92 81, Fax: +49 36 41 77-99 88ir(at)analytik-jena.com, www.analytik-jena.com[HUG#1383411] --- End of Message --- Analytik Jena AGKonrad-Zuse-Stra? 1 Jena GermanyWKN: 521350 ;ISIN: DE0005213508 ;Index:Prime All Share;Listed: Freiverkehr in B? Stuttgart,Freiverkehr in Hanseatische Wertpapierb? zu Hamburg,Freiverkehr in B? Berlin,Freiverkehr in B? D?ldorf,Freiverkehr in Bayerische B? M?en,Freiverkehr in Nieders?sische B? zu Hannover,Prime Standard in Frankfurter Wertpapierb?,Regulierter Markt in Frankfurter Wertpapierb?;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.02.2010 - 03:35 Uhr
Sprache: Deutsch
News-ID 1010257
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Jena
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 117 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Analytik Jena in the First Quarter with a Stable Business Development
"
steht unter der journalistisch-redaktionellen Verantwortung von
Analytik Jena AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
